Effect of Intravenously Administered Estrogen in Cardiovascular Disease

Treatment of Diabetic Retinopathy With Estrogens

“…Marmorston and her colleagues (76) have demonstrated that significant reduction in the serum cholesterol level and the cholesterol/phospholipid ratio can be achieved in male patients with myocardial infarction who are given daily doses of estrogen so moderate that there is no development of breast tenderness. Gitman and Green‐blatt (77) reported diminution in the serum concentration of beta lipoproteins of the S f 12–20 and 20–100 classes following a single intravenous dose of Premarin in a patient with coronary insufficiency. Relatively small doses of methyl‐testosterone can counteract completely these biochemical effects of estrogens when the two are administered simultaneously (17).…”

Oral and Intravenous Estrogens in the Treatment and Prevention of Bleeding Associated With Long‐term Anticoagulant Therapy

“…This is also evident when estrogenic substances are administered orally to men with myocardial infarction (71–74). Diminution in the serum concentration of beta lipoproteins in the S f 12–20 and 20–100 classes following a single intravenous dose of Premarin in a patient with coronary insufficiency has been reported (75). The effect on the serum cholesterol and phospholipid levels tends to be maximal and maintained after ninety days of therapy, little difference being observed between the effects of ethinyl estradiol (Estinyl), diethylstilbestrol, Manvene and Premarin.…”

“…Prolonged administration of estrogens does not appear to lessen this metabolic effect, and no tolerance or resistance to the hormone has been observed (66). In addition to the marked reduction in serum lipid and lipoprotein concentrations, striking disappearance of xanthomatous lesions has been induced by oral estrogen therapy in patients with primary hypercholesterolemic xanthomatosis or idiopathic hyperlipemia (75–77). Relatively small doses of methyltestosterone can counteract completely the biochemical effects of estrogens when the two are administered simultaneously (75).…”

Newer Clinical and Laboratory Studies in the Aged: Vi. Serum Lipids, Lipoproteins and Atherogenic Index in “Normal“ Subjects 80–100 Years of Age†

“…The cause of higher values in females still needs explanation. Various observers have attempted to explain the differences on the basis of endocrinologic make‐up, and have administered estrogenic substances intravenously, in humans (34, 35) and in chicks, in an attempt to shift lipoprotein patterns (36). This work is still inconclusive and further data must be collected.…”